Audit of tumour histopathology reviewed by a regional oncology centre.
Affiliation
Department of Histopathology, Bolton General Hospital.Issue Date
1995-03
Metadata
Show full item recordAbstract
AIMS: To analyse the diagnostic differences in reporting tumour histopathology between a district general hospital and a regional oncology centre. METHODS: Tumour histopathology reports (n = 227) extracted from Bolton General Hospital files between 1988 and 1992 were compared with the corresponding Christie Hospital (oncology centre) reports, the same material having been seen at both hospitals. RESULTS: Diagnostic agreement existed in 77% of all cases. The incidence of major discrepancies was 8.37%. Of the diagnoses, 19 (36%) cases involved major discrepancies and 34 (64%) cases minor discrepancies. Most discrepancies occurred in the lymphoma group and involved subclassification of Hodgkin's and non-Hodgkin's lymphoma. Ki1 anaplastic large cell lymphoma and T cell rich B cell lymphoma were problematic diagnoses. The correct grading of follicle centre cell lymphomas using the Kiel classification was another problem area. In 19 cases certain aspects of immunohistochemistry produced discrepancies. In one case an incorrect diagnosis was made at the oncology centre and in another both centres gave an incorrect diagnosis. CONCLUSIONS: Areas of diagnostic difficulty mainly involve the subclassification of lymphomas. Review of tumour pathology by experts is recommended, at least in certain categories, to ensure correct diagnosis and uniformity in subclassification of tumours.Citation
Audit of tumour histopathology reviewed by a regional oncology centre. 1995, 48 (3):245-9 J. Clin. Pathol.Journal
Journal of Clinical PathologyDOI
10.1136/jcp.48.3.245PubMed ID
7730487Type
ArticleLanguage
enISSN
0021-9746ae974a485f413a2113503eed53cd6c53
10.1136/jcp.48.3.245
Scopus Count
Collections
Related articles
- Management of lymphoma patients in a cancer unit: an audit of 15 years' experience in a district general hospital.
- Authors: Chester JD, Clark CJ, Gouldesbrough DR, Bogle SM, Bradley CJ, Parker D
- Issue date: 2001
- Audit of tumour pathology reviewed by a regional oncology centre.
- Authors: Thomas K
- Issue date: 1995 Jul
- A prospective comparison of fine-needle aspiration cytology and histopathology in the diagnosis and classification of lymphomas.
- Authors: Landgren O, Porwit MacDonald A, Tani E, Czader M, Grimfors G, Skoog L, Ost A, Wedelin C, Axdorph U, Svedmyr E, Björkholm M
- Issue date: 2004
- Histopathological diagnoses in soft tissue tumours: an experience from a tertiary centre in Malaysia.
- Authors: Jalaludin ND, Mohd Dusa N, Hassan MR, Abd Shukor N
- Issue date: 2017 Dec
- [Histopathological diagnostic concordance in bone and soft tissue sarcomas between two comprehensive cancer centers from eastern and western Europe: a collaborative experience].
- Authors: Somcutian O, Buiga R, Galatir M, Tudor Eniu D, Rachieru C, Coza D, Terrier P
- Issue date: 2015 Jan
Related items
Showing items related by title, author, creator and subject.
-
Treatment for non small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future.O'Brien, M; van Meerbeeck, J; Surmont, V; Faivre-Finn, Corinne (2012)
-
Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.Ingham, S; Warwick, J; Buchan, I; Sahin, S; O'Hara, Catherine; Moran, Anthony; Howell, Anthony; Evans, D; Centre for Health Informatics, Institute of Population Health, The University of Manchester, Manchester, UK. (2013-06)Mutations in BRCA1/2 genes confer ovarian, alongside breast, cancer risk. We examined the risk of developing ovarian cancer in BRCA1/2-positive families and if this risk is extended to BRCA negative families.
-
AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate.Lillian, S; De Bono, J; Higano, C; Shapiro, G; Brugger, W; Mitchell, P; Colebrook, S; Klinowska, T; Barry, S; Dean, Emma J; et al. (2016-12)